RETRACTED: No deleterious effect of lockdown due to COVID-19 pandemic on glycaemic control, measured by glucose monitoring, in adults with type 1 diabetes.

abstract：BACKGROUND:Recent evidence emphasizes the importance of maintaining normoglycemia in critically ill patients to reduce morbidity and mortality. Different analytical methods of varying accuracy exist for obtaining and measuring blood glucose in critically ill patients. The purpose of this study was to determine if there...

journal_title：Diabetes technology & therapeutics

authors： Slater-MacLean L,Cembrowski G,Chin D,Shalapay C,Binette T,Hegadoren K,Newburn-Cook C

更新日期：2008-06-01 00:00:00

abstract：BACKGROUND:Performance of continuous glucose monitors (CGMs) may be lower when glucose levels are changing rapidly, such as occurs during physical activity. Our aim was to evaluate accuracy of a current-generation CGM during moderate-intensity exercise in type 1 diabetes (T1D) pregnancy. SUBJECTS AND METHODS:As part o...

journal_title：Diabetes technology & therapeutics

authors： Kumareswaran K,Elleri D,Allen JM,Caldwell K,Nodale M,Wilinska ME,Amiel SA,Hovorka R,Murphy HR

更新日期：2013-03-01 00:00:00

abstract：:Chronic hyperglycemia, as assessed by hemoglobin A1c (HbA1c) levels, has been associated with the development of microvascular and macrovascular complications of diabetes. Several studies have shown that acute hyperglycemia can add to the effect of chronic hyperglycemia in inducing tissue damage. Acute hyperglycemia c...

journal_title：Diabetes technology & therapeutics

authors： Marcovecchio ML,Lucantoni M,Chiarelli F

更新日期：2011-03-01 00:00:00

abstract：OBJECTIVE:We sought to cross validate several metrics for quality of glycemic control, hypoglycemia, and hyperglycemia. RESEARCH DESIGN AND METHODS:We analyzed the mathematical properties of several metrics for overall glycemic control, and for hypo- and hyperglycemia, to evaluate their similarities, differences, and ...

journal_title：Diabetes technology & therapeutics

authors： Rodbard D

更新日期：2018-05-01 00:00:00

abstract：BACKGROUND:For patients with type 1 diabetes mellitus, a bihormonal artificial endocrine pancreas system utilizing glucagon and insulin has been found to stabilize glycemic control. However, commercially available formulations of glucagon cannot currently be used in such systems because of physical instability characte...

journal_title：Diabetes technology & therapeutics

authors： Caputo N,Jackson MA,Castle JR,El Youssef J,Bakhtiani PA,Bergstrom CP,Carroll JM,Breen ME,Leonard GL,David LL,Roberts CT Jr,Ward WK

更新日期：2014-11-01 00:00:00

abstract：BACKGROUND:A1chieve(®) (Novo Nordisk A/S, Bagsværd, Denmark) was a prospective, multicenter, noninterventional study in 66,726 people with type 2 diabetes mellitus (T2DM) in 28 countries beginning biphasic insulin aspart 30 (aspart premix), insulin detemir, or insulin aspart in routine clinical care. SUBJECTS AND METH...

journal_title：Diabetes technology & therapeutics

authors： Shah S,Yang W,Hasan MI,Malek R,Molskov Bech O,Home P

更新日期：2013-11-01 00:00:00

abstract：: Background: We aimed to explore insulin pump settings in breastfeeding women with type 1 diabetes. Methods: Thirteen unselected breastfeeding women with type 1 diabetes on insulin pump therapy were included consecutively from A...

journal_title：Diabetes technology & therapeutics

authors： Nørgaard SK,Nørgaard K,Roskjær AB,Mathiesen ER,Ringholm L

更新日期：2020-04-01 00:00:00

abstract：BACKGROUND:Obesity surgery elicits complex changes in glucose metabolism that are difficult to observe with discontinuous glucose measurements. We aimed to evaluate glucose variability after gastric bypass by continuous glucose monitoring (CGM) in a real-life setting. METHODS:CGM was performed for 4.2 ± 1.3 days in th...

journal_title：Diabetes technology & therapeutics

authors： Hanaire H,Bertrand M,Guerci B,Anduze Y,Guillaume E,Ritz P

更新日期：2011-06-01 00:00:00

abstract：BACKGROUND:Faster aspart is insulin aspart (IAsp) in a new formulation, which in continuous subcutaneous insulin infusion (CSII) in subjects with type 1 diabetes has shown a faster onset and offset of glucose-lowering effect than IAsp. METHODS:This double-blind, randomized, crossover active-controlled trial compared 2...

journal_title：Diabetes technology & therapeutics

authors： Bode BW,Johnson JA,Hyveled L,Tamer SC,Demissie M

更新日期：2017-01-01 00:00:00

abstract：BACKGROUND:During the proteomic era, one of the most rapidly growing areas in biomedical research is biomarker discovery, particularly using proteomic technologies. The urinary proteome is known to be a valuable field of study and has become one of the most attractive subdisciplines in clinical proteomics for human dis...

journal_title：Diabetes technology & therapeutics

authors： Riaz S,Alam SS,Srai SK,Skinner V,Riaz A,Akhtar MW

更新日期：2010-12-01 00:00:00

abstract：BACKGROUND:Patients with diabetes do daily self-monitoring of blood glucose (SMBG). For such patients, we devised an engine that predicts not only the expected blood glucose level at the next meal but also the pending risks of hypoglycemia. The purpose of this study was to validate the predictions and provide evidence ...

journal_title：Diabetes technology & therapeutics

authors： Albisser AM,Sakkal S,Wright C

更新日期：2005-06-01 00:00:00

abstract：:Empowerment plays significant roles in the complex management of type 2 diabetes. International guidelines have provided recommendations on management of Muslims who fast during Ramadan. However, there remains a lack of patient-centered epistemic tool to empower healthcare providers and patients in managing diabetes d...

journal_title：Diabetes technology & therapeutics

authors： Lum ZK,See Toh WY,Lim SM,Rusli KDB,Abdul Shakoor SAKK,Tsou KYK,Chew DEK,Dalan R,Kwek SC,Othman N,Lian JX,Lee JY

更新日期：2018-10-01 00:00:00

abstract：:Type 2 diabetes is thought to develop as a result of progressive beta-cell dysfunction in the setting of insulin resistance, leading to increased risks of microvascular and macrovascular complications. Type 2 diabetes is currently treated with diet and exercise, followed by oral drug therapy, and finally exogenous ins...

journal_title：Diabetes technology & therapeutics

authors： Kendall DM,Kim D,Maggs D

更新日期：2006-06-01 00:00:00

abstract：: Objective: To assess the degree, duration, mean absolute relative difference (MARD), and error analysis of discrepant values per continuous glucose monitoring (CGM) systems after hydroxyurea (HU) administration. Research Design and Methods: ...

journal_title：Diabetes technology & therapeutics

authors： Tellez SE,Hornung LN,Courter JD,Abu-El-Haija M,Nathan JD,Lawson SA,Elder DA

更新日期：2020-12-30 00:00:00

abstract：:Continuous glucose monitoring (CGM) systems have been available for more than 15 years by now. However, market uptake is relatively low in most countries; in other words, relatively few patients with diabetes use CGM systems regularly. One major reason for the reluctance of patients to use CGM systems is the costs ass...

journal_title：Diabetes technology & therapeutics

authors： Heinemann L,DeVries JH

更新日期：2016-02-01 00:00:00

abstract：: Background: The Medtronic MiniMed™ 670G system adjusts basal insulin delivery in response to continuous glucose monitoring levels and is already in use in clinical practice. We tested the home-based feasibility of the new MiniMed advanced hybrid closed-loop (AHCL) system, ...

journal_title：Diabetes technology & therapeutics

authors： Nimri R,Grosman B,Roy A,Nir J,Fisch Shvalb N,Kurtz N,Loewenthal N,Gillon-Keren M,Muller I,Atlas E,Phillip M

更新日期：2020-12-08 00:00:00

abstract：AIMS:The aim was to investigate the prevalence of diabetic sensorimotor polyneuropathy (DSPN) and cardiovascular autonomic neuropathy (CAN) in a Danish population of young adults with type 1 diabetes (T1D) using both established and novel measuring modalities. Furthermore, to investigate the association between continu...

journal_title：Diabetes technology & therapeutics

authors： Christensen MMB,Hommel EE,Jørgensen ME,von Scholten BJ,Fleischer J,Hansen CS

更新日期：2018-11-21 00:00:00

abstract：BACKGROUND:Implanted insulin pumps using the peritoneal route provide long-term improvement of glucose control compared with subcutaneous insulin therapy in type 1 diabetes (T1D) patients. The stability of insulin preparation is critical for a safe use in implanted pumps. Insuman implantable(®) (400 IU/mL) (Sanofi-Aven...

journal_title：Diabetes technology & therapeutics

authors： Schaepelynck P,Riveline JP,Renard E,Hanaire H,Guerci B,Baillot-Rudoni S,Sola-Gazagnes A,Catargi B,Fontaine P,Millot L,Martin JF,Tachouaft H,Jeandidier N,EVADIAC Group.

更新日期：2014-09-01 00:00:00

abstract：:Treatments for type 1 diabetes have advanced significantly over recent years. There are now multiple hybrid closed-loop systems commercially available and additional systems are in development. Challenges remain, however. This review outlines the recent advances in closed-loop systems and outlines the remaining challe...

journal_title：Diabetes technology & therapeutics

authors： Jackson M,Castle JR

更新日期：2020-07-01 00:00:00

abstract：BACKGROUND:Balance is sensed through peripheral and central receptors and mediated by central control through the brain and spinal cord. Although some evidence exists as to the areas of the brain involved and how processing of data occurs in young individuals, nothing has been published on people with diabetes. The pur...

journal_title：Diabetes technology & therapeutics

authors： Petrofsky JS,Alshammari F,Lee H,Yim JE,Bains G,Khowailed IA,Deshpande PP,Potnis P,Tse F,Cavalcanti P

更新日期：2012-11-01 00:00:00

abstract：:There are three main issues in non-invasive (NI) glucose measurements: namely, specificity, compartmentalization of glucose values, and calibration. There has been progress in the use of near-infrared and mid-infrared spectroscopy. Recently new glucose measurement methods have been developed, exploiting the effect of ...

journal_title：Diabetes technology & therapeutics

authors： Khalil OS

更新日期：2004-10-01 00:00:00

abstract：OBJECTIVE:Exercise is a cornerstone of diabetes therapy in type 1 diabetes mellitus (DMT1) patients. The type of exercise is important in determining the propensity to hypoglycemia. We assessed, by continuous glucose monitoring (CGM), the glucose profiles during and in the following 20h after a session of two different...

journal_title：Diabetes technology & therapeutics

authors： Maran A,Pavan P,Bonsembiante B,Brugin E,Ermolao A,Avogaro A,Zaccaria M

更新日期：2010-10-01 00:00:00

abstract：:Most previous attempts at the development of a "smart tattoo" for glucose monitoring in diabetes--implantable fluorescent microspheres that can be implanted intradermally and interrogated transdermally using light--have focused on the encapsulation of a competitive binding assay for glucose within hydrogel microsphere...

journal_title：Diabetes technology & therapeutics

authors： Brown JQ,Srivastava R,Zhu H,McShane MJ

更新日期：2006-06-01 00:00:00

abstract：BACKGROUND:Various insulin delivery systems have been considered for systemic absorption other than injections. Although the ocular route has been suggested, its use is limited by the amount of insulin absorbed systemically via eyes. In order to improve the absorption rate of insulin into systemic circulations, the eff...

journal_title：Diabetes technology & therapeutics

authors： Xuan B,McClellan DA,Moore R,Chiou GC

更新日期：2005-10-01 00:00:00

abstract：BACKGROUND:Long-term treatment is necessary to slow the progression of type 2 diabetes (T2D). Here, we examined the safety and efficacy of 6 years of treatment with exenatide once weekly (QW) among patients with T2D in the DURATION-1 trial. METHODS:The study enrolled patients aged ≥16 years with T2D treated primarily ...

journal_title：Diabetes technology & therapeutics

authors： Henry RR,Klein EJ,Han J,Iqbal N

更新日期：2016-11-01 00:00:00

abstract：BACKGROUND:Currently, two systems for continuous tissue glucose monitoring (CGM) (Dexcom® G5 [DG5] and FreeStyle Libre [FL]) are intended to replace blood glucose monitoring (BGM) and, according to manufacturer labeling, are distributed as such in some jurisdictions, including the United States and the European Union. ...

journal_title：Diabetes technology & therapeutics

authors： Freckmann G,Link M,Pleus S,Westhoff A,Kamecke U,Haug C

更新日期：2018-08-01 00:00:00

abstract：BACKGROUND:The value of self-monitoring of blood glucose (SMBG) for persons with type 2 diabetes who do not use insulin remains controversial. This observational study compares the likelihood of medication adherence and change in glycated hemoglobin (A1C) for non-insulin-using patients using SMBG versus those not using...

journal_title：Diabetes technology & therapeutics

authors： Virdi N,Daskiran M,Nigam S,Kozma C,Raja P

更新日期：2012-09-01 00:00:00

abstract：BACKGROUND:Glucose monitoring based on sampling skin interstitial fluid (ISF) is being developed as an alternative to fingerstick blood glucose monitoring. Time delays between rapidly changing levels of glucose in blood and interstitial fluid have been reported in the literature to be between 5 and 20 minutes. This stu...

journal_title：Diabetes technology & therapeutics

authors： Smith A,Yang D,Delcher H,Eppstein J,Williams D,Wilkes S

更新日期：1999-04-01 00:00:00

abstract：BACKGROUND:Diabetes mellitus is rare in young infants and neonates. Continuous subcutaneous insulin infusion (CSII) is used most frequently for insulin treatment in this age group. However, the individual doctor's experience is scarce because of the low prevalence of diabetes in this age. For this study patients treate...

journal_title：Diabetes technology & therapeutics

authors： Kapellen TM,Heidtmann B,Lilienthal E,Rami-Merhar B,Engler-Schmidt C,Holl RW

更新日期：2015-12-01 00:00:00

abstract：BACKGROUND:Automated insulin management features of the MiniMed® 640G sensor-augmented pump system include suspension in response to predicted low sensor glucose (SG) values ("suspend before low"), suspension in response to existing low SG values ("suspend on low"), and automatic restarting of basal insulin delivery up...

journal_title：Diabetes technology & therapeutics

authors： Zhong A,Choudhary P,McMahon C,Agrawal P,Welsh JB,Cordero TL,Kaufman FR

更新日期：2016-10-01 00:00:00